Exhibit 99.2 Vlad Vitoc, MD, MBA Chief Executive Officer 444 West Lake Street, Suite 1700 - Chicago, IL 60606 (312) 416-8592 vvitoc@maiabiotech.com (215) 971-5488 maiabiotech.com Telomere Targeting Immunotherapies for Cancer MAIA is an immuno-oncology company focused on the development and commercialization of first-in-class drugs intended to meaningfully improve and extend the lives of people with hard-to-treat cancers. We are exploring new science for cancer therapy utilizing a novel dual mechanism of action: telomere targeting and immunogenicity. Our lead program is THIO, a first-in-class anticancer agent in clinical development for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients. Company Highlights Clinical Programs THIO-101 THIO-102 (planning) Ph 2 trial of THIO + Libtayo® (cemiplimab) Ph 2 trial of THIO + checkpoint inhibitors • Go-to-market trial in second-line+ NSCLC • Go-to-market trial in late line of therapy in multiple • Objectives: select most efficacious dose and expand tumor types: Colorectal Cancer (CRC), into pivotal trial; file for accelerated approval in Hepatocellular Carcinoma (HCC, 90% of primary 2025 type of liver cancers), Small Cell Lung Cancer • Enrollment completed earlier than expected in Feb (SCLC) and Solid Tumors of any type (ST) 2024; trial nearing completion • Objectives: select most efficacious combination by • Topline data expected mid-2024; long-term data on tumor type and expand into pivotal trials (12+ second half of 2024 possible market entry indications) • Preliminary Overall Response Rate for best dose • File for accelerated approvals in 2026 and beyond 180mg: ü 38% ORR in third-line vs. 6-10% with SoC THIO-103 (planning) ü 75% of patients crossed 5.8 months OS Ph 2/3 trial of THIO + checkpoint inhibitors threshold in third-line • First-line NSCLC and SCLC • Preliminary Disease Control Rate (DCR), best • Expand to Breast, Prostate, Pancreatic, Ovarian, predictor for overall survival benefit (meta-analysis Gastric Cancer, etc. of 74 trials worldwide): • Objectives: confirmatory for accelerated approvals ü 85% DCR in third-line vs. 25-35% with Soc from THIO-101 and THIO-102 THIO is a Unique Direct Telomere Targeting Agent • Potential to be used in combination with other anticancer and immune therapies • Novel dual mechanism of action: telomere targeting + immunogenic • 3 FDA Orphan Drug Designations: HCC, SCLC, and Glioblastoma • Excellent efficacy: achieved complete and durable responses in HCC in vivo models (peer-reviewed published study) • Featured in multiple renowned scientific publications including Cancer Cell and Nature Partnership with Regeneron Cap Table • Clinical supply agreement: Regeneron provides NYSE American: MAIA Libtayo® for THIO-101 1 2 • Equivalent to $32M non-dilutive participation Share Price $4.36 Float 14M (largest financing move to date) 1 Market Cap $95M Insider • Potential to expand existing relationship and target 2 Holdings 27% FD Shares new companies 2 Cash $8M 2 35M Outstanding 1 2. As of Apr 25, 2024 1. As of May 30, 2024

MAIA Biotechnology’s goal is to bring revolutionary cancer treatments to the market, with the only direct telomere targeting agent in clinical development. MAIA is developing agents for the top tumor types markets globally. Significant Market Opportunity • Cancer is the most dominant of the age-related disease categories and has life altering impacts in the lives of patients and their close ones • The number of people aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million • Approximately 40% of people alive today are projected to be diagnosed with a cancer type in their lifetime, and 20% will die of it • NSCLC is the leading tumor type: Mortality 1.7M / Sales $32B (2022) • CRC is second: Mortality 1M / Sales $20B (2022) Strong and Growing IP Portfolio • Potential for receiving NCE marketing exclusivity • 5 patents issued, 29 patent applications pending Next Generation Potential Telomere Targeting Therapeutics in R&D • 84 new molecules engineered; same mechanism of action as THIO • Following THIO to commercial stage within 4-5 years Robust Pipeline PHASE 1 PHASE 2 PHASE 3 COLLABORATION & RIGHTS THIO Telomere targeting agent Worldwide rights Patient Enrollment (THIO → Libtayo®) NSCLC-2+ THIO-101 owned by MAIA Complete Worldwide rights Ph 2 THIO-102 CRC, HCC, SCLC, ST (THIO → CPI) owned by MAIA Planning Worldwide rights Ph 2/3 THIO-103 NSCLC-1, SCLC-1 (THIO → CPI) owned by MAIA Planning nd 2 Generation Telomere targeting agents IND MAIA-2021-020 Multiple Ind. Enabling Developed in-house IND MAIA-2022-012 Multiple Ind. Enabling fully-owned by MAIA MAIA-2021-029 Multiple Indications Vlad Vitoc, MD, MBA Founder, Chairman, and Chief Executive Officer • 24+ years in Pharma/Biotech: Commercial, Medical, • 12 compounds launched across 20+ tumor types • Leadership roles at Bayer (Nexavar), Astellas (Tarceva, Xtandi), Cephalon (Treanda), Novartis (Zometa), and Incyte (Jakafi) Scan QR Code to DISCLAIMER: This information is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy any security access our or related financial instrument or to participate in any trading strategy. The summary may include “forward-looking statements” with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934 and are intended to be covered by the safe harbor provisions for investor 2 forward looking statements. This information is supplied from sources we believe to be reliable but we cannot guarantee accuracy. This document is presentation furnished to you solely for your information.